Preclinical study demonstrates synergistic chemo-photothermal therapy via an activatable polyprodrug nanoreactor in cancer models, highlighting improved multimodal imaging and tumor penetration.
Anticancer nanomedicine-based multimodal imaging and synergistic therapy hold great promise in cancer diagnosis and therapy owing to their abilities to improve therapeutic efficiency and reduce unnecessary side effects, producing promising clinical prospects. Herein, we integrated chemotherapeutic drug camptothecin (CPT) and near-infrared-absorbing new indocyanine green (IR820) into a single system by charge interaction and obtained a tumor-microenvironment-activatable PCPT SS /IR820 nanoreactor to perform thermal/fluorescence/photoacoustic-imaging-guided chemotherapy and photothermal therapy simultaneously. Specifically, the generated PCPT SS /IR820 showed an excellent therapeutic agent loading content and size stability, and the trials in vitro and in vivo suggested that the smart PCPT SS /IR820 could deeply permeate into tumor tissues due to its suitable micellar size. Upon near-infrared laser irradiation, the nanoreactor further produced a terrific synergism of chemo–photo treatment for cancer therapy. Therefore, the PCPT SS /IR820 polyprodrug-based nanoreactor holds outstanding promise for multimodal imaging and combined dual therapy.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: